What's Happening?
Hackensack Meridian Health has partnered with SpotitEarly, an Israeli startup, to study an innovative cancer detection method that combines artificial intelligence with the scent detection capabilities of trained dogs. SpotitEarly's approach involves a breath-based, at-home early detection test, which the company plans to roll out in the U.S. next year. The collaboration will focus on validating this non-invasive method through a clinical trial called the PINK Study, which will involve 2,000 participants and focus initially on breast cancer detection. The study aims to demonstrate high sensitivity and specificity in early cancer detection, with plans to expand to other cancer types in the future.
Why It's Important?
This partnership represents a novel approach to cancer screening, addressing the significant gap in early detection methods for many cancer types. By combining AI with the natural olfactory abilities of dogs, SpotitEarly aims to provide a more accessible and less invasive screening option. This could lead to earlier detection of cancers, improving survival rates and reducing the burden on healthcare systems. The initiative aligns with Hackensack Meridian Health's mission to transform cancer care through proactive prevention, potentially setting a new standard in early cancer detection.
What's Next?
The PINK Study will begin with breast cancer detection, with plans to expand to lung and prostate cancers. SpotitEarly is preparing for an FDA pre-submission as part of its regulatory strategy. The company also plans to open a lab in the U.S. within the next 18 months, which will facilitate the broader implementation of its detection technology. The success of this collaboration could lead to widespread adoption of this innovative screening method, potentially revolutionizing cancer detection and prevention.
